Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the ...
The multicenter open-label study demonstrated a statistically significant reduction of urinary oxalate excretion in recurrent calcium oxalate kidney stone patients with hyperoxaluria treated with ALLN-177 relative to baseline (P=0.0084). ALLN-177 was ...
PharmiWeb.com (press release) - Wed, 18 Mar 2015 05:22

OHF Summer Gala Will Honor 'Stone Crushers' From Mamaroneck, Cold Spring
The OHF is the only foundation in the world dedicated to improving the care and treatment and finding a cure for Oxalosis, Primary Hyperoxaluria and related kidney stone diseases. Kaskel is the director of pediatric nephrology at the Children's ...
The Daily Voice - Sat, 14 Mar 2015 14:36

2015 OHF Summer Gala announces honorees
OHF is the only Foundation in the world dedicated to improving the care and treatment and finding a cure for Oxalosis, Primary Hyperoxaluria (PH) and related stone diseases. Garden City residents became aware of this rare disease after a child from our ...
Garden City News - Thu, 05 Mar 2015 17:07

Powerful Steps For Goldman Sachs With BDC IPO
... the GSAM Liberty Harbor portfolio management team. Prior to joining in 2006, Mr. McGovern served as a managing director in the Global Investment Group at Amaranth Advisors and is on the Board of Directors for the Oxalosis & Hyperoxaluria Foundation.
Seeking Alpha (registration) - Tue, 17 Mar 2015 19:23

Tekmira Provides Corporate Update and Announces Year-End 2014 Results
In November 2014, Tekmira entered into collaboration with Dicerna for the use of its technology to develop, manufacture, and commercialize products related to the treatment of primary hyperoxaluria Type 1. Tekmira received $3.0 million from Dicerna in ...
CNNMoney - Thu, 12 Mar 2015 12:52

Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q4 2014 ...
Dicerna continues to make positive progress in line with the guidance we've given and with the development timelines we've laid out for our development programs for two key product candidates, DCR-PH1, our program for Primary Hyperoxaluria Type 1 or ...
Seeking Alpha (registration) - Thu, 12 Mar 2015 18:07

Dicerna Announces Fourth Quarter and Full Year 2014 Financial and ...
Business Wire (press release) - Thu, 12 Mar 2015 12:52

Massive Losers Of Yesterday - Alnylam Pharmaceuticals, (NASDAQ:ALNY), J C ...
Its product development programs also comprise ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the ...
wsnewspublishers - Thu, 19 Mar 2015 05:22

Tekmira Pharmaceuticals Corporation: Tekmira Provides Corporate Update and ...
In November 2014, Tekmira entered into collaboration with Dicerna for the use of its technology to develop, manufacture, and commercialize products related to the treatment of primary hyperoxaluria Type 1. Tekmira received $3.0 million from Dicerna in ...
The Wall Street Transcript - Sat, 14 Mar 2015 23:56


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014